Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol
Top Cited Papers
Open Access
- 30 July 2013
- journal article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 20 (13), 4224-4230
- https://doi.org/10.1245/s10434-013-3145-9
Abstract
Purpose This nationwide study evaluated results of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis of colorectal origin in the Netherlands following a national protocol. Methods In a multi-institutional study prospective databases of patients with peritoneal carcinomatosis (PC) from colorectal cancer and pseudomyxoma peritonei (PMP) treated according to the Dutch HIPEC protocol, a uniform approach for the CRS and HIPEC treatment, were reviewed. Primary end point was overall survival and secondary end points were surgical outcome and progression-free survival. Results Nine-hundred sixty patients were included; 660 patients (69 %) were affected by PC of colorectal carcinoma and the remaining suffered from PMP (31 %). In 767 procedures (80 %), macroscopic complete cytoreduction was achieved. Three-hundred and thirty one patients had grade III–V complications (34 %). Thirty-two patients died perioperatively (3 %). Median length of hospital stay was 16 days (range 0–166 days). Median follow-up period was 41 months (95 % confidence interval (CI), 36–46 months). Median progression-free survival was 15 months (95 % CI 13–17 months) for CRC patients and 53 months (95 % CI 40–66 months) for PMP patients. Overall median survival was 33 (95 % CI 28–38 months) months for CRC patients and 130 months (95 % CI 98–162 months) for PMP patients. Three- and five-year survival rates were 46 and 31 % respectively in case of CRC patients and 77 and 65 % respectively in case of PMP patients. Conclusions The results underline the safety and efficacy of cytoreduction and HIPEC for PC from CRC and PMP. It is assumed the uniform Dutch HIPEC protocol was beneficial.Keywords
This publication has 23 references indexed in Scilit:
- A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trialBMC Cancer, 2013
- Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapyEuropean Journal of Surgical Oncology, 2012
- Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancerBritish Journal of Surgery, 2012
- Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841Journal of Clinical Oncology, 2012
- A Comparative Study of Complete Cytoreductive Surgery Plus Intraperitoneal Chemotherapy to Treat Peritoneal Dissemination From Colon, Rectum, Small Bowel, and Nonpseudomyxoma AppendixAnnals of Surgery, 2010
- Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal OriginJournal of Clinical Oncology, 2009
- Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: A prospective studyEuropean Journal of Surgical Oncology, 2005
- ?Axillary Recurrence After a Negative Sentinel Node Biopsy?: Editorial CommentAnnals of Surgical Oncology, 2005
- Long-Term Survival of Peritoneal Carcinomatosis of Colorectal OriginAnnals of Surgical Oncology, 2004
- Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapyBritish Journal of Surgery, 2004